Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60p -0.44% 136.90p 137.00p 137.30p 139.10p 136.80p 137.40p 1,119,081.00 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 72.0 -1.9 1.2 114.1 927.65

Vectura Group Share Discussion Threads

Showing 5226 to 5249 of 5250 messages
Chat Pages: 210  209  208  207  206  205  204  203  202  201  200  199  Older
DateSubjectAuthorDiscuss
07/12/2016
10:47
diesel... indeed... and it's trend lines over a period that actually has meaning. The day to day gyrations or trying to make some meaning out of day to day rises in the am's and drops in the pm''s or vice-versa are utterly meaningless. Once Novartis make their announcement... and there is no reason to suppose it will not be good for VEC... then the trend line should continue to rise quite nicely over the next few months. The full yr results are virtually guaranteed to be in line or even exceed forecasts, there is loadsa dosh in the bank and 2017 news flow is looking good. There really isn't much not to like about this stock IMO... unless your neurotic... if you are you shouldn't be in pharma!!!!
dontay
07/12/2016
10:10
As I posted yesterday, we may have dropped and be far lower than any here had hoped but since Sep we have been on I rising trend line and it's interesting watch intraday levels test and bounce off this.
diesel
07/12/2016
09:53
alexchry, yes, frustration at delays are normal, but the suggestions that the recent back off of the share price is due to leaking of bad news is pure bullpoo IMO. Novartis as a mega huge company are involved in the withholding of classified information from the numerous partnerships they have built with companies both large and tiny... all over the planet... and are well versed in ensuring there are Zero leaks onto the market. Any suggestions to the contrary are ridiculous and the result of worry and neurosis! There is no fundamental reason behind the recent drop after the good interims... other than the pi sector being being fed up with the delay and concerns over the litigation. It IS quite possible... and IMO much more likely that the recent drop has been caused by a couple of big operators working in tandem to manipulate the share price to their eventual advantage. For every seller there is a buyer!
dontay
07/12/2016
07:33
Dontay - I'm sure you're right about Novartis doing things when they are good and ready but it's not just posters on this board that think they are taking longer than expected but Vectura themselves who forecast that marketing would begin in H2 2016 and have now put their forecast back to H1 2017. Vectura must be as frustrated as some of their shareholders. Hopefully the strong finish yesterday on reasonable volume means there are better times ahead.
alexchry
07/12/2016
07:27
Gargoyle2 - this was posted on here, 5121, and is old news, report issued in late October. The news we want is to hear that Novartis are going ahead with marketing of Ultibro.
alexchry
07/12/2016
07:07
From another board: Vectura has transformed with Skyepharma, says Numis A merger with Skyepharma has had a transformative effect for biotech firm Vectura (VEC), according to Numis Securities. Analyst Stefan Hamill retained his ‘buy’ recommendation and target price of 252p on the stock, which slipped 1.6p or 1.1% to 138p yesterday.‘The transformative effects of the Skyepharma merger started to become clear at Vectura’s recent interims, with a significant step-up in revenues and underlying cashflow, an increase in the proportion of recurring revenues in the business, and underlying organic revenue growth strong at 305-plus driven by the ongoing global roll-out of seven inhalers containing Vectura technology,’ he said. With five potential new product launches in 2017, Hamill said he can ‘see Vectura sustaining its industry leading sales and profit growth over the next few years, propelling the share price’.
gargoyle2
06/12/2016
19:44
Target prices now are 2-2,5£ before merger vec was 2£ it was stupid not to sell merger killed share price and we have only sellers no buyers it will never come back to premerger level of 2£
a1ord53
06/12/2016
19:14
Even for a huge company like Norvartis it will take time to get all their short, medium and long term marketing ducks in row once they have collated all the information... possibly even more so in light of the excellent and very recent GOLD report. They are under no pressure and will make their announcement when they are good and ready.As for the current share price gyrations, IMO it's nothing to be concerned about... there could even be some short term manipulation going on in the background in preparation for a recovery, I wouldn't be surprised to see it suddenly jump back to150p plus in the blink of any eye, even without any input from Norvartis.
dontay
06/12/2016
13:53
Ok then im wrong down in the morning perhaps up in afternoon well for now anyhow all change im on here a lot at the moment as in the middle of france at our sons and wife place with 3 grand children all under 5 driving me mad and also very bored
pooroldboy55
06/12/2016
12:10
The way the share price is going think has a lot to do with Novartis as yet not going forward, lets hope they have not got something up there sleeve
pooroldboy55
06/12/2016
12:07
On a positive note we seem to be in a rising trend starting in Sep, and if today's trend holds we have bounced off the rising resistance trend line. Like everyone, still waiting!
diesel
06/12/2016
11:33
Popper Joe - I expect Vectura are a bit confused, they originally had the marketing starting in H2 2016 and have now slipped it into H1 2017. After all the good reports, it seems strange than Novartis seem to be dragging their heels, it is very worrying although we might find out later that there was a good reason for the delay and extra trial.
alexchry
06/12/2016
11:25
Could one of the wise heads explain this to me please: If the recent GOLD guidance places Breezhaler at the top of the list for recommended treatments, then why would there be any doubt about Novartis going ahead and marketing the product? I have read that they were awaiting the results of some other head-to-head comparison, but I am slightly confused as to why they wouldn't try to ride the wave of positive comments in the GOLD report. Sorry if this sounds a bit naive!!!
popper joe
06/12/2016
09:49
I said at start of september could see this going to a pound at this rate will be there by end of year.we have seen a drop from almost £2 thats some fall, what will happen if all the good news in the pipe line turn out to be bad.There is something very very wrong here!!!!!!!!!!!!!!!!!!!!! share price down on low numbers but never up
pooroldboy55
06/12/2016
09:42
The analysts are forecasting jam tomorrow but since the merger we have only had stale bread. A failed major COPD trial, GSK litigation and the Novartis delay. The good news has been the strong trading but that was expected. It is no wonder the share price has been weak, what's needed is a positive marketing statement from Novartis. It would be a bonus if we heard good news about the litigation as well but nothing optimistic was said at the interims. If we get that positive statement from Novartis then that should underpin the share price until the FDA decision in May. If that decision is positive then we may see some of the analysts' predictions being realised.
alexchry
06/12/2016
09:28
What is really going on?
tcarter66208
06/12/2016
08:50
If we could spend all these compliments we would all be rich!
popper joe
06/12/2016
08:38
Vectura has transformed with Skyepharma says Numis A merger with Skyepharma has had a transformative effect for biotech firm Vectura (VEC), according to Numis Securities. Analyst Stefan Hamill retained his ‘buy’ recommendation and target price of 252p on the stock, which slipped 1.6p or 1.1% to 138p yesterday. ‘The transformative effects of the Skyepharma merger started to become clear at Vectura’s recent interims, with a significant step-up in revenues and underlying cashflow, an increase in the proportion of recurring revenues in the business, and underlying organic revenue growth strong at 305-plus driven by the ongoing global roll-out of seven inhalers containing Vectura technology,’ he said. With five potential new product launches in 2017, Hamill said he can ‘see Vectura sustaining its industry leading sales and profit growth over the next few years, propelling the share price’.
robow
06/12/2016
08:25
Well that makes a change down from the start will we end up blue? Don't think so
pooroldboy55
02/12/2016
17:53
PJ, agree far from clear. I take it that there were additional patents that came into play after the original patent licencing deal was signed and maybe opting out of the original option to licence agreement falls foul of free use of these later added patents. Could well be barking up the wrong tree...
carpadium
02/12/2016
17:27
I doubt it will make any difference whatsoever to any potential future partnerships between GSK and VEC whoever wins. It's nothing personal, it's purely business... and there is no shame in businesses trying to gain an advantage... and there is every chance that there will be an amicable settlement out of court anyway.
dontay
02/12/2016
17:18
Is anyone able to offer a clear explanation of what this issue with GSK is about? My reading of the situation is that the 2010 agreement between the two companies covered the licensed use by GSK of technologies that VEC had patents over. It would appear that those patents expired in 2016 and GSK are now refusing to pay a license fee for the continued use of now un-patented technology. Am I missing something, because from my naive VEC shareholder's point of view, I can't see that we have much of an argument.
popper joe
02/12/2016
16:58
Not if they are suing in the US!
fhmktg
02/12/2016
16:50
Four months and counting since litigation initiated. Maybe the Christmas spirit will prevail and relationship restored but wouldn't put money on that happening.
carpadium
Chat Pages: 210  209  208  207  206  205  204  203  202  201  200  199  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20161207 18:18:34